Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 6878Lung Neoplasms 5110Small Cell Lung Carcinoma 1168Breast Neoplasms 856Neoplasms 762Colorectal Neoplasms 671Melanoma 566Ovarian Neoplasms 506Neoplasm Metastasis 481Pancreatic Neoplasms 473Adenocarcinoma of Lung 399Stomach Neoplasms 397Prostatic Neoplasms 370Head and Neck Neoplasms 368Carcinoma, Renal Cell 351Esophageal Neoplasms 337Squamous Cell Carcinoma of Head and Neck 325Mesothelioma, Malignant 324Colonic Neoplasms 294Mesothelioma 289Urinary Bladder Neoplasms 263Brain Neoplasms 255Uterine Cervical Neoplasms 243Triple Negative Breast Neoplasms 223Sarcoma 198Endometrial Neoplasms 196Carcinoma, Hepatocellular 187NSCLC 167Pleural Effusion, Malignant 161Kidney Neoplasms 161

Interventions

Pemetrexed 2Gemcitabine 2Cisplatin 2Carboplatin 2CP protocol 2durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Non Small Cell Lung Carcinoma NSCLC × Thoracic × Clear all
NCT02542293 2026-05-01

NEPTUNE

AstraZeneca

Phase 3 Active not recruiting
953 enrolled 29 charts
Thoracic

Non Small Cell Lung Carcinoma NSCLC

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

AstraZeneca

Phase 3 Active not recruiting
669 enrolled 54 charts
Thoracic

Non Small Cell Lung Carcinoma NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡